Last reviewed · How we verify

NCT05563376

Fontan-Sprechstunde

Recruiting now NA Last updated 3 October 2022
What this trial tests

NA trial testing Univentricular Hearts in Univentricular Heart in 200 participants. Currently enrolling.

Timeline
1 September 2020
Primary endpoint
1 September 2031
1 September 2041

Quick facts

Lead sponsorUniversity of Erlangen-Nürnberg Medical School
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment200
Start date1 September 2020
Primary completion1 September 2031
Estimated completion1 September 2041
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 6 to 60, any sex, with Univentricular Heart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias. The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Univentricular Heart

Currently open trials in the same condition.

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing